CompletedPhase 2NCT00931944

Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)

Studying Amyotrophic lateral sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Knopp Biosciences
Principal Investigator
Merit Cudkowicz, M.D., MSc
NeuroClinical Trials Unit (Massachusetts General Hospital)
Intervention
KNS-760704(drug)
Enrollment
74 enrolled
Eligibility
21-80 years · All sexes
Timeline
20092013

Study locations (19)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00931944 on ClinicalTrials.gov

Other trials for Amyotrophic lateral sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Amyotrophic lateral sclerosis

← Back to all trials